New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
07:41 EDTALDXAldeyra reports Q2 EPS ($1.56), may not compare to one estimate (53c)
Net loss per share for the respective period includes the effect of the change in fair value of derivative instruments carried as liabilities on the balance sheet that are marked to market at the end of each reporting period. As of June 30, there were no derivative liabilities outstanding as a result of the net exercise of those instruments.
News For ALDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 27, 2015
16:40 EDTALDXAldeyra files to sell 423,056 shares of common stock for holders
16:37 EDTALDXAldeyra files to sell 2.23M shares of common stock for holders
Subscribe for More Information
March 26, 2015
08:34 EDTALDXAldeyra opens enrollment in NS2 Phase II clinical trial
Subscribe for More Information
March 25, 2015
10:00 EDTALDXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:16 EDTALDXAldeyra initiated with a Buy at Chardan
Subscribe for More Information
March 24, 2015
08:33 EDTALDXAldeyra announces first patient enrolled in Phase II clinical trial of NS2
Aldeyra Therapeutics announced that it has enrolled the first patient in its Phase II clinical trial of NS2 for the treatment of Sjögren-Larsson Syndrome, or SLS. The trial is being held at the University of Nebraska University Medical Center, the leading treatment center in the United States for SLS.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use